Anti-vascular endothelial growth factor biosimilars for macular degeneration

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the efficacy and safety of the anti-VEGF biosimilars compared with their reference product in people with neovascular AMD.

This is a protocol.

Published:

4 August 2023

Authors:

Sunaga T, Maeda M, Hasegawa T, Mason AN, Noma H, Ota E

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Sunaga T, Maeda M, Hasegawa T, Mason AN, Noma H, Ota E. Anti-vascular endothelial growth factor biosimilars for macular degeneration (Protocol). Cochrane Database of Systematic Reviews 2023, Issue 8. Art. No.: CD015804. DOI: 10.1002/14651858.CD015804.